Search Within

Chau Dang

Formats
  1. Journal Article (132)
  2. Meeting Abstract (121)
  3. Guidelines (8)
  4. Book Section (4)
  5. Review (3)
  6. Book Whole (1)
  7. Editorial (1)
  8. Miscellaneous (1)
  9. Research Letter (1)
Groups
  1. Breast Medicine Service (272)
  2. Department of Medicine (272)
  3. Solid Tumor Oncology Division (272)
  4. Survivorship Research (272)
  5. Population Sciences Research Program (119)
  6. Epidemiology and Biostatistics (92)

More Groups

People
  1. Clifford Hudis (111)
  2. Larry Norton (76)
  3. Richard Steingart (49)
  4. Anthony Yu (46)
  5. Shanu Modi (42)
  6. Sujata Patil (41)

More People

Years
  1. 2025 (3)
  2. 2024 (12)
  3. 2023 (15)
  4. 2022 (18)
  5. 2021 (12)
  6. 2020 (20)

More Years

Publications
  1. Journal of Clinical Oncology (67)
  2. Cancer Research (42)
  3. Breast Cancer Research and Treatment (23)
  4. Annals of Oncology (10)
  5. Clinical Breast Cancer (7)
  6. Clinical Cancer Research (7)

More Publications

Publishers
  1. American Society of Clinical Oncology (69)
  2. American Association for Cancer Research (50)
  3. Springer (33)
  4. Oxford University Press (22)
  5. Elsevier Inc. (16)
  6. American Medical Association (11)

More Publishers

Results (272)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Dose-dense (DD) doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel (P) with trastuzumab (T) and lapatinib (L) in HER2/neu-positive breast cancer is not feasible due to excessive diarrhea: Updated results
    Meeting Abstract

    Dang, C.; Lin, N.; Moy, B.; Come, S.; Lake, D.; Theodoulou, M.; Troso-Sandoval, T.; Dickler, M.; Gorsky, M.; D'Andrea, G.; more...
    Cancer Research (2009)

    Fulltext@MSK | Save
  • Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer
    Journal Article

    Dang, C.
    Current Breast Cancer Reports (2009)

    Fulltext@MSK | Save
  • The role of adjuvant anthracyclines for breast cancer treatment: Can we use molecular predictors?
    Journal Article

    Dang, C.; Hudis, C.
    Current Breast Cancer Reports (2009)

    Fulltext@MSK | Save
  • Tolerance of bevacizumab in an older patient population: The Memorial Sloan-Kettering Cancer Center (MSKCC) experience
    Meeting Abstract

    Richardson, S.; Dickler, M. N.; Dang, C. T.; Hudis, C. A.; Traina, T. A.
    Journal of Clinical Oncology (2008)

    Fulltext@MSK | Save
  • Dose-dense (dd) doxorubicin-cyclophosphamide (AC) X 4 and short-term changes in left ventricular ejection fraction (LVEF) alone or with bevacizumab (B) in patients (pts) with early stage breast cancer (BC)
    Meeting Abstract

    Morris, P. G.; Dickler, M. N.; McArthur, H. L.; Traina, T. A.; Nulsen, B.; Steingart, R. M.; Rugo, S.; Norton, L.; Hudis, C. A.; Dang, C. T.
    Journal of Clinical Oncology (2008)

    Fulltext@MSK | Save
  • Preliminary safety results of dose-dense (dd) doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel (P) with trastuzumab (T) and lapatinib (L) in HER2 overexpressed/amplified breast cancer (BCA)
    Meeting Abstract

    Dang, C. T.; Lin, N. U.; Lake, D.; Dickler, M. N.; Modi, S.; Seidman, A. D.; Steingart, R. M.; Norton, L.; Winer, E. P.; Hudis, C. A.
    Journal of Clinical Oncology (2008)

    Fulltext@MSK | Save
  • New treatment paradigms in metastatic breast cancer
    Book Whole


    CMPMedica (2008)

    Fulltext@MSK | Save
  • Dose-dense (dd) doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel (P) with trastuzumab (T) and lapatinib (L) in HER2 overexpressed/amplified breast cancer (BC): First safety results
    Meeting Abstract

    Dang, C.; Lin, N.; Lake, D.; Theodoulou, M.; Drullinsky, P.; Gorsky, M.; Chen, C.; Norton, L.; Winer, E.; Hudis, C.
    Annals of Oncology (2008)

    Fulltext@MSK | Save
  • Pharmacokinetics and tolerability of exemestane in combination with raloxifene in postmenopausal women with a history of breast cancer
    Journal Article

    Traina, T. A.; Poggesi, I.; Robson, M.; Asnis, A.; Duncan, B. A.; Heerdt, A.; Dang, C.; Lake, D.; Moasser, M.; Panageas, K.; more...
    Breast Cancer Research and Treatment (2008)

    Fulltext@MSK | Save
  • The taxane limbo: How low can we go?
    Journal Article

    Hudis, C.; Dang, C.
    JNCI: Journal of the National Cancer Institute (2008)

    Fulltext@MSK | Save